Analysed DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) News Sources
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
09-03-2026
yahoo.com
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
02-03-2026
yahoo.com
Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
27-02-2026
yahoo.com
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
10-02-2026
yahoo.com
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
04-02-2026
yahoo.com
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
28-01-2026
yahoo.com
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
21-01-2026
yahoo.com
What is the current price of DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS)?
The current price of DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) is $0.3716.
DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) since the previous trading day is $-0.0584.
DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) since the previous trading day is -13.5814%.
What is the most recent average sentiment score for DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS)?
The most recent average sentiment score for DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) is 74 out of 100.
What is the most recent average sentiment for DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS)?
The most recent sentiment for DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) is .
SEC-8K** Filing Available For DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.